Urolithin A: The Mitophagy Compound With Phase 2 Clinical Trial Data (2026)

Why Mitophagy Matters

The mitochondria in a 60-year-old cell are not the same as those in a 20-year-old cell. Over decades, mitochondria accumulate damage — to their DNA, their membranes, their respiratory chain proteins. Damaged mitochondria produce less ATP and more reactive oxygen species (ROS). The cell's quality control system — mitophagy — should clear these damaged organelles and allow biogenesis of new, healthy replacements.

The problem: mitophagy efficiency declines with age. Damaged mitochondria accumulate rather than being cleared. Energy production falls. Oxidative stress rises. The downstream effects touch every tissue in the body — muscles fatigue earlier, neurons become more vulnerable, immune cells function less effectively.

Urolithin A is the most clinically advanced compound for restoring mitophagy — and it has something most longevity compounds lack: Phase 2 human clinical trial data confirming the mechanism works in human tissue.

The Microbiome Bottleneck

Urolithin A is produced by gut bacteria (primarily Gordonibacter, Ellagibacter, and Adlercreutzia species) when they metabolise ellagitannins — polyphenols found in pomegranate, walnuts, and some berries.

The critical issue: only approximately 40% of people have the gut microbiome composition needed to convert ellagitannins to Urolithin A. This is not simply a matter of eating more pomegranates — the conversion requires specific bacterial species that are absent or insufficient in 60% of the population.

Research classifies people into three urolithin producer categories:

• Metabotype A: Efficient Urolithin A producers (~40% of people)
• Metabotype B: Produce Urolithin A plus other urolithins (~45%)
• Metabotype 0: Produce negligible urolithins (~15%)

Supplementing Urolithin A directly bypasses this bottleneck entirely — the compound is delivered pre-formed regardless of microbiome status.

^[1]

The Clinical Evidence

Phase 1: Safety and Bioavailability (Nature Medicine, 2016)

The landmark Ryu et al. study demonstrated that oral Urolithin A is bioavailable in humans, produces dose-dependent plasma levels, and induces mitophagy gene expression in human muscle biopsies. This was the first evidence that dietary compounds could activate mitophagy in humans at achievable oral doses.

Phase 1b: Human Molecular Signature (Nature Metabolism, 2019)

Andreux et al. conducted a more detailed molecular characterisation in healthy older adults. 500mg/day and 1000mg/day Urolithin A for 4 weeks:

• Significantly increased mitophagy-related gene expression in muscle (PINK1, Parkin, ATG7, LC3B)
• Improved mitochondrial gene expression
• Well-tolerated with no serious adverse events

^[4]

This confirmed that the doses achievable with supplementation produce the intended molecular effect in human tissue.

Phase 2 RCT: The Definitive Evidence (Cell Metabolism, 2022)

Singh et al. enrolled 66 sedentary older adults (aged 65–90) in a randomised, double-blind, placebo-controlled trial. Groups: Urolithin A 500mg/day, 1000mg/day, or placebo for 4 months.

Primary outcomes — 1000mg group vs placebo:

• 6-minute walk distance: Significantly improved — the most clinically meaningful functional endurance measure
• Mitochondrial gene expression: Significantly increased (OXPHOS genes, mitophagy markers)
• Plasma inflammatory markers: IL-6, C-reactive protein significantly reduced
• Muscle strength: Trend toward improvement (not statistically significant at 4 months)

^[2]

500mg vs 1000mg: The 1000mg group showed consistently better outcomes, suggesting a dose-response relationship. This drives the recommendation for 1000mg/day rather than 500mg/day.

Safety: No serious adverse events in any group. Mild GI discomfort in a small percentage of participants — well within acceptable limits.

Mechanism in Detail

PINK1/Parkin Mitophagy Activation

In healthy mitochondria, PINK1 is rapidly degraded before accumulating. In damaged (depolarised) mitochondria, PINK1 accumulates on the outer membrane, recruits Parkin, which ubiquitinates outer membrane proteins. Ubiquitin-binding adaptor proteins (p62, NDP52) then link the tagged mitochondrion to the autophagosome for degradation.

Urolithin A activates this pathway — specifically by maintaining mitochondrial membrane potential monitoring efficiency and upregulating PINK1/Parkin expression.

PGC-1α and Mitochondrial Biogenesis

After clearing damaged mitochondria, the cell needs to replace them with fresh, healthy organelles. PGC-1α is the master transcription factor driving this biogenesis. Urolithin A upregulates PGC-1α, ensuring that mitophagy (destruction) is paired with biogenesis (creation) — a net improvement in mitochondrial quality.

AMPK Activation

Urolithin A activates AMPK — the energy-sensing kinase that promotes catabolic and housekeeping pathways when energy is limited. AMPK activation drives autophagy (including mitophagy) and inhibits mTORC1, complementing Rapamycin's mechanism from a different angle.

Anti-Inflammatory Effects

The significant reduction in IL-6 and CRP in the Phase 2 trial reflects Urolithin A's anti-inflammatory effects beyond mitophagy — likely through NF-κB pathway suppression and reduced ROS from improved mitochondria.

Dosage and Sourcing

Dose

Based on the Phase 2 trial data: 1000 mg/day is the evidence-supported dose. 500mg/day shows some benefit but consistently less than 1000mg.

Timing

Morning, with or without food. Urolithin A absorption is not significantly affected by food.

Product Quality

Urolithin A product quality varies enormously. Timeline Nutrition's Mitopure is the product used in all published clinical trials — it is the only form with Phase 2 human evidence at specified doses. Generic alternatives may contain different isomers, lower purity, or incorrect amounts.

If cost is a consideration, look for products specifying:

• Urolithin A (not "pomegranate extract containing urolithins")
• ≥95% purity by HPLC
• Third-party tested
• Confirmed urolithin A content (not total urolithins)

The Mitochondrial Stack

Frequently Asked Questions

Is Mitopure worth the premium over generic Urolithin A? Mitopure is the only form with Phase 2 human data at specified doses. For those prioritising evidence-backed products, this is meaningful. For those comfortable with extrapolation, quality-tested generics at 1000mg/day are a reasonable alternative.

Does eating pomegranates provide enough Urolithin A? Only for the ~40% who are efficient urolithin producers. Even for them, conversion efficiency is variable and the dose is uncertain. Supplementation provides consistent delivery regardless of microbiome.

How long before effects are measurable? Mitophagy gene expression changes occur within 4 weeks (Nature Metabolism 2019). Functional improvements (walk distance, muscle strength) required 4 months in the Phase 2 trial. Longevity benefits operate over years.

Can I take it with Rapamycin? Yes — Urolithin A's mitophagy induction and Rapamycin's mTOR inhibition are complementary autophagy-promoting mechanisms. This combination is used in advanced longevity protocols.

Is it safe during chemotherapy? Not established. The immunomodulatory and cellular housekeeping effects could theoretically interact with chemotherapy mechanisms. Discuss with oncologist.

Related Substances

• View Urolithin A
• View SS-31
• View NMN
• View MOTS-c

Related Research

• Urolithin A + SS-31: The Mitochondrial Synergy Stack
• SS-31 (Elamipretide): Reversing Mitochondrial Aging at the Inner Membrane
• Taurine + NMN Longevity Stack: The Anti-Aging Combination
• The Mitochondrial Synergy: Why SS-31 Must Precede MOTS-c